MG
SRRA

Michael Gelband’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Michael Gelband’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-19,538
Closed -$626K – 2744
2022
Q1 		$626K Buy
+19,538
New +$561K 0.01% 1403
2020
Q1 		– Sell
-620
Closed -$8K – 1822
2019
Q4 		$8K Buy
+620
New +$8.09K ﹤0.01% 1475

Other funds holding SRRA

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VI
Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Michael Gelband's SRRA Position: Q2 2022 in Review

Michael Gelband sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q2 2022, closing a stake of 19,538 shares — an estimated $626K sold.

Michael Gelband first reported a position in SRRA in Q4 2019 and held it in 2 quarters. The position peaked at $626K in Q1 2022. 109 funds tracked by Wall St. Rank hold SRRA as of Q2 2022.

  • Michael Gelband reported no remaining Sierra Oncology, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Michael Gelband sold 19,538 Sierra Oncology, Inc. Common Stock shares in Q2 2022, an estimated $626K.
  • Michael Gelband first reported a position in Sierra Oncology, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • Michael Gelband's Sierra Oncology, Inc. Common Stock position peaked at $626K in Q1 2022.
  • 109 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.